期刊
CLINICAL LUNG CANCER
卷 9, 期 1, 页码 59-60出版社
CIG MEDIA GROUP, LP
DOI: 10.3816/CLC.2008.n.010
关键词
epidermal growth factor receptor; non-small-cell lung cancer; vancomycin
类别
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We report on a patient with known non-small-cell lung cancer who developed Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据